|
CN104224702A
|
|
Fulvestrant-containing medicine preparation
|
|
CN103884846A
|
|
Detection method for biological activity of liraglutide
|
|
CN104677971A
|
|
Capillary electrophoresis detection method of EPO mutant
|
|
CN103893744A
|
|
Pharmaceutical preparation for treating diabetes and preparation method thereof
|
|
CN102792158A
|
|
Fine structure determination method of enoxaparin sodium based on capillary electrophoresis
|
|
CN102796197A
|
|
Human serum albumin-granulocyte colony stimulating factor (HAS-GCSF) mutant and preparation method thereof
|
|
CN102746383A
|
|
Synthesis method of goserelin
|
|
CN102648978A
|
|
Stable protein pharmaceutical preparation and preparation method thereof
|
|
CN102690329A
|
|
Purification production method of goserelin polypeptide
|
|
CN102128907A
|
|
RP-HPLC detection method for recombinant human granulocyte colony stimulating factors
|
|
CN102336829A
|
|
Method for producing recombinant human bone morphogenetic protein-2 mature peptide
|
|
CN102234310A
|
|
Polyethylene glycol modified protein separating and purifying method
|
|
CN101670096A
|
|
Medicinal preparation containing exenatide
|
|
CN101525364A
|
|
Crystal form of fulvestrant and preparation method thereof
|
|
CN101792441A
|
|
Crystal forms of palonosetron hydrochloride and preparation method thereof
|
|
CN101255157A
|
|
Crystal system of chlorhydric acid palonosetron and preparation method thereof
|
|
CN101444618A
|
|
Pharmaceutical preparation containing exenatide
|
|
CN101157691A
|
|
Production technique of hydrochloric acid palonosetron
|
|
CN101352573A
|
|
Recombinant human granulocyte colony stimulating factor lysine defect body modified by polyethyleneglycol
|
|
CN102329388A
|
|
Production method for Pichia pastoris expression recombinant human interleukin 11
|
